<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188031</url>
  </required_header>
  <id_info>
    <org_study_id>R06-0302</org_study_id>
    <nct_id>NCT01188031</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam
      Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2
      mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs
      Inc.Â®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult
      volunteers administered under fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: This was a single-center, randomized, two-way
      crossover study conducted under fasting conditions Official Title: A Relative Bioavailability
      Study of 2 mg Alprazolam Oral Disintegrating Tablets under Fasting Conditions

      Further study details as provided by Actavis Elizabeth LLC:

      Primary Outcome Measures:

      Rate and Extend of Absorption
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>72hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ALPRAZOLAM ORALLY DISINTEGRATING TABLETS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIRAVAM TM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NIRAVAM TM 2 mg orally disintegrating tablets, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG</intervention_name>
    <description>A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions</description>
    <arm_group_label>ALPRAZOLAM ORALLY DISINTEGRATING TABLETS</arm_group_label>
    <other_name>NIRAVAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIRAVAM TM 2 mg orally disintegrating tablets, single dose</intervention_name>
    <description>B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions</description>
    <arm_group_label>NIRAVAM TM</arm_group_label>
    <other_name>ALPRAZOLAM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who met the following criteria were included in the study.

          1. Volunteers who were informed of the nature of the study and who read, reviewed, and
             signed the informed consent prior to Period I dosing.

          2. Volunteers who completed the screening process within 28 days prior to Period I
             dosing.

          3. Volunteers who were healthy adult men and women 18 years of age or older at the time
             of dosing.

          4. Volunteers who had a body mass index (BMI) between 18-32 kg/nr', inclusive, and
             weighed at least 110 lbs.

          5. Volunteers who were healthy as documented by the medical history, physical examination
             (including but may not be limited to an evaluation of the cardiovascular,
             gastrointestinal, respiratory and central nervous systems), vital sign assessments,
             12-lead electrocardiogram (ECG), clinical laboratory assessments, and by general
             observations. Any abnormalities/deviations form the normal range that were considered
             clinically relevant by the study physician and investigator were evaluated for
             individual cases, documented in study files, and agreed upon by both the study
             physician and investigator prior to enrolling the volunteer in this study and for
             continued enrollment.

          6. Female volunteers ofpostmenopausal (no menses) status for at least 1 year and has a
             serum FSH level 2: 30 mlU/mL or surgically sterile (bilateral tubal ligation,
             bilateral oophorectomy, or hysterectomy.)

        Exclusion Criteria:

        Subjects who met any ofthe following criteria were excluded from the study.

          1. Volunteers who reported receiving any investigational drug within 28 days prior to
             Period I dosing.

          2. Volunteers who reported any presence or history of a clinically significant disorder
             involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic,
             hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined
             by the clinical investigator(s).

          3. Volunteers whose clinical laboratory test values outside the accepted reference range
             and, when confirmed on re-examination, were deemed clinically significant.

          4. Volunteers who demonstrated a reactive screen for hepatitis B surface antigen,
             hepatitis C antibody, or HIV antibody.

          5. Volunteers who reported a history of allergic response(s) to alprazolam or related
             drugs.

          6. Volunteers who reported the use of any systemic prescription medication in the 14 days
             prior to Period I dosing.

          7. Volunteers who reported the use of any drug known to induce or inhibit hepatic drug
             metabolism in the 28 days prior to Period I dosing.

          8. Volunteers who reported a history ofclinically significant allergies including drug
             allergies.

          9. Volunteers who reported a clinically significant illness during the 4 weeks prior to
             Period I dosing (as determined by the clinical investigators).

         10. Volunteers who reported a history of drug or alcohol abuse addiction or abuse within
             the past year.

         11. Volunteers who demonstrated a positive drug abuse screen for this study prior to
             Period I dose administration.

         12. Volunteers who currently used tobacco products.

         13. Volunteers who reported donating greater than 150 mL ofblood within 28 days prior to
             Period I dosing. All subjects were advised not to donate blood for four weeks after
             completing the study.

         14. Volunteers who donated plasma (e.g. plasmapheresis) within 14 days prior to Period I
             dosing. All subjects were advised not to donate plasma for four weeks after completing
             the study

         15. Volunteers who demonstrated a positive pregnancy screen (females only).

         16. Volunteers who were currently pregnant or breastfeeding (females only).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D. Carlson,, Pharm.D,</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://chem.sis.nlm.nih.gov/chemidplus/ProxyServlet?objectHandle=DBMaint&amp;actionHandle=default&amp;nextPage=jsp/chemidlite/ResultScreen.jsp&amp;TXTSUPERLISTID=0028981977</url>
    <description>ALPRAZOLAM</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <last_update_submitted>August 23, 2010</last_update_submitted>
  <last_update_submitted_qc>August 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>ALPRAZOLAM</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

